Kuros Biosciences’ Post

We’re thrilled to share the publication of the EMBOLISE Trial in the New England Journal of Medicine! This landmark multicenter, prospective, randomized controlled trial demonstrates the potential of the Onyx™ Liquid Embolic System (LES) for middle meningeal artery (MMA) embolization. Therapy represented may not be available in all geographies, subject to regulatory and/or medical practices. Discover the key findings: https://bit.ly/4fOzTHc Product usage represented may not be approved or cleared in all markets.

Thanks to all of you who have expressed interest in the StarTric TriClover technology for Tricuspid Valve repair, after it has been presented a few weeks ago at the last TCT in Washington D.C., both at the Shark Tank Competition and at two scientific sessions. For detailed info, please refer to the #JACC paper “TriClover: Novel Transcatheter Technique to Repair the Tricuspid Valve With High Effectiveness and Wide Indications” - Michele De Bonis, Maurizio Taramasso, Marco Gard, Ottavio Alfieri (https://lnkd.in/ewcDzTNd). The results published in the paper, obtained on pathological ex vivo and chronic in vivo models, show that TriClover has the potential to be effective also in very complex pathological configurations of the Tricuspid Valve, and to address Tricuspid Regurgitation for a vast population of patients who would not have today a viable therapeutic option. Based on this evidence, we are now heading toward finalisation of the Investigational Device for clinical validation. Stay tuned for more scientific communications, in the coming months, on the results of TriClover validation. https://lnkd.in/ewcDzTNd

Register to witness my inaugural webinar presentation and please let me know if you have pressing questions you’d like answered about your IHC biomarker development plans. #IHC #biomarkerdriven

After Resmetirom, hopefully we will have a few other approveed options for MASH Rx soon. Major Phase 2 MASH Trial Updates: Tirzepatide: 🔸44-62% resolution of MASH at 52 wks. 🔸~50% of participants ≥ 1 stage improvement in fibrosis at 52 wks. Survodutide: 🔸~35% of participants with ≥ 1 stage improvement in fibrosis at 48 wks.

Venova Medical, Inc. has announced enrolment of the first participants in the company’s VENOS-2 early feasibility study, assessing the Velocity percutaneous arteriovenous fistula (pAVF) system. https://lnkd.in/gx7npqyV

#EPeeps, don’t miss EP Lab Digest's Atrial Fibrillation Topic Center, which features dedicated content on #AFib! Highlighted this month: WATCHMAN™ FLX and the OPTION Clinical Trial: An Alternative to Lifetime Oral Anticoagulant Use in Post-ablation Patients https://okt.to/VuCUAo

This is clinical mass spectrometry technology that has the potential to revolutionise paraprotein detection, monitoring and classification. It’s an exciting time!

SELUTION SLR™ Drug-Eluting Balloon features a unique sustained drug release mechanism and is part of the largest randomized clinical trial comparing #DEB vs. DES in coronary de-novo lesions. Thanks Dr Andrew Ladwiniec for sharing your insights on the potential of SELUTION SLR™ DEB that may revolutionize #PCI! #Sirolimus

BiVacor, the California-based medical device company known for its total artificial heart (TAH) technology, has completed the initial phase of an early feasibility study (EFS) first approved by the U.S. Food and Drug Administration (FDA) in December 2023. 

This exciting agreement is a reflection of the emerging clinical data from our Phase 1 study of etakafusp alfa (AB248). Initial data demonstrate a highly differentiated clinical pharmacodynamic profile with unprecedented levels of selective CD8+ T cell activation as well as initial evidence of anti-tumor effect including confirmed objective responses. #LightUpWhatMatters #NSCLC https://lnkd.in/eSnYWxGe